DZ3364A1 - Agent therapeutique cristallin - Google Patents

Agent therapeutique cristallin

Info

Publication number
DZ3364A1
DZ3364A1 DZ013364A DZ013364A DZ3364A1 DZ 3364 A1 DZ3364 A1 DZ 3364A1 DZ 013364 A DZ013364 A DZ 013364A DZ 013364 A DZ013364 A DZ 013364A DZ 3364 A1 DZ3364 A1 DZ 3364A1
Authority
DZ
Algeria
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
agent
therapeutic
Prior art date
Application number
DZ013364A
Other languages
English (en)
French (fr)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ3364A1 publication Critical patent/DZ3364A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
DZ013364A 2000-07-28 2001-07-18 Agent therapeutique cristallin DZ3364A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
DZ3364A1 true DZ3364A1 (fr) 2002-02-07

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013364A DZ3364A1 (fr) 2000-07-28 2001-07-18 Agent therapeutique cristallin

Country Status (46)

Country Link
EP (1) EP1305314B1 (no)
JP (1) JP2004505087A (no)
KR (1) KR100457937B1 (no)
CN (1) CN1207297C (no)
AP (1) AP1400A (no)
AR (1) AR032628A1 (no)
AT (1) ATE286901T1 (no)
AU (2) AU7269001A (no)
BG (1) BG107266A (no)
BR (1) BR0112734A (no)
CA (1) CA2417264C (no)
CZ (1) CZ2003126A3 (no)
DE (1) DE60108398T2 (no)
DO (1) DOP2001000217A (no)
DZ (1) DZ3364A1 (no)
EA (1) EA004681B1 (no)
EC (1) ECSP034454A (no)
EE (1) EE200300045A (no)
ES (1) ES2231521T3 (no)
GE (1) GEP20053494B (no)
HK (1) HK1055954A1 (no)
HR (1) HRP20030061A2 (no)
HU (1) HUP0302982A3 (no)
IL (1) IL153226A0 (no)
IN (1) IN2002MU01649A (no)
IS (1) IS6626A (no)
MA (1) MA26931A1 (no)
MX (1) MX233602B (no)
MY (1) MY117831A (no)
NO (1) NO324220B1 (no)
NZ (1) NZ523226A (no)
OA (1) OA12337A (no)
PA (1) PA8523501A1 (no)
PE (1) PE20020277A1 (no)
PH (1) PH12001001922B1 (no)
PL (1) PL365133A1 (no)
PT (1) PT1305314E (no)
SK (1) SK572003A3 (no)
SV (1) SV2001000570A (no)
TN (1) TNSN01112A1 (no)
TW (1) TWI285643B (no)
UA (1) UA72631C2 (no)
UY (1) UY26854A1 (no)
WO (1) WO2002010171A1 (no)
YU (1) YU4703A (no)
ZA (1) ZA200301457B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
WO2006120552A2 (en) * 2005-05-12 2006-11-16 Pfizer Inc. ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134442C (zh) * 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
GEP20053494B (en) 2005-04-25
IS6626A (is) 2002-11-18
HRP20030061A2 (en) 2003-04-30
NO20030416D0 (no) 2003-01-27
ES2231521T3 (es) 2005-05-16
CZ2003126A3 (cs) 2004-02-18
DE60108398D1 (de) 2005-02-17
IL153226A0 (en) 2003-07-06
EP1305314B1 (en) 2005-01-12
ECSP034454A (es) 2003-03-10
HUP0302982A3 (en) 2005-01-28
AR032628A1 (es) 2003-11-19
BG107266A (bg) 2003-07-31
IN2002MU01649A (no) 2004-12-11
NO20030416L (no) 2003-02-05
EP1305314A1 (en) 2003-05-02
EA200300079A1 (ru) 2003-06-26
DE60108398T2 (de) 2005-12-22
TWI285643B (en) 2007-08-21
ZA200301457B (en) 2004-04-28
MX233602B (es) 2006-01-10
PH12001001922B1 (en) 2006-11-21
KR20030016430A (ko) 2003-02-26
WO2002010171A1 (en) 2002-02-07
KR100457937B1 (ko) 2004-11-20
JP2004505087A (ja) 2004-02-19
MXPA03000856A (es) 2003-06-06
UA72631C2 (uk) 2005-03-15
YU4703A (sh) 2006-01-16
CN1207297C (zh) 2005-06-22
HK1055954A1 (en) 2004-01-30
PA8523501A1 (es) 2002-10-24
AU2001272690B2 (en) 2005-12-08
EA004681B1 (ru) 2004-06-24
SV2001000570A (es) 2002-09-03
ATE286901T1 (de) 2005-01-15
NZ523226A (en) 2003-07-25
EE200300045A (et) 2004-12-15
UY26854A1 (es) 2002-02-28
NO324220B1 (no) 2007-09-10
PE20020277A1 (es) 2002-05-11
HUP0302982A2 (hu) 2003-12-29
CA2417264C (en) 2007-06-12
AP2001002234A0 (en) 2001-09-30
CN1444585A (zh) 2003-09-24
BR0112734A (pt) 2004-08-10
MY117831A (en) 2004-08-30
PT1305314E (pt) 2005-04-29
PL365133A1 (en) 2004-12-27
MA26931A1 (fr) 2004-12-20
CA2417264A1 (en) 2002-02-07
AP1400A (en) 2005-04-28
SK572003A3 (en) 2004-05-04
OA12337A (en) 2006-05-15
DOP2001000217A (es) 2002-10-30
TNSN01112A1 (fr) 2005-11-10
AU7269001A (en) 2002-02-13

Similar Documents

Publication Publication Date Title
DK1637127T3 (da) Terapeutisk mikroskum
DK1199054T3 (da) Væskefrakturhånddel
DE60124662T8 (de) Karosseriestruktur
NO20025580L (no) Medisinsk anordning
DE69924365D1 (de) Massagegerät
DK1335678T3 (da) Oralt behandlingssystem
AR028622A1 (es) Derivados de tropano utiles en terapia
DE60044269D1 (de) Krankenliege
PT1235558E (pt) Agentes terapeuticos
NO20032122D0 (no) Forbedret behandling
DE60009451D1 (de) Massagegerät
DE10193450D2 (de) Gehörschutzstöpsel
DZ3364A1 (fr) Agent therapeutique cristallin
GB0030067D0 (en) Therapeutic agent
NO20016301D0 (no) Terapeutiske midler
NO20030946L (no) Medisinske sammensetninger
ATA7922000A (de) Elektromedizinisches gerät
DK1305314T3 (da) Krystallinsk terapeutisk middel
DE60107973D1 (de) Gewebehandlungszubereitung
SE0003368D0 (sv) Therapeutic compounds
SE0004825D0 (sv) Therapeutic compounds
SE0004826D0 (sv) Therapeutic compounds
DE10193217D2 (de) Therapiegerät
FI4458U1 (fi) Savusauna
SE0000819D0 (sv) Skin preparation